Statistik Asas
| LEI | 213800T44AN9XSAOY605 |
| CIK | 1358575 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Cipher Pharmaceuticals Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| February 22, 2017 |
Cipher Pharmaceuticals FORM 15/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15/A Amendment No. 1 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 000-36734 Cipher Pharmaceuticals Inc. (Exact name of regi |
|
| January 17, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-36734 Cipher Pharmaceuticals Inc. (Exact name of registrant as specifie |
|
| December 31, 2016 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2016 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 (905) 602 |
|
| December 31, 2016 |
AMENDMENT NO. 5 TO Securities Purchase Agreement Exhibit 99.1 AMENDMENT NO. 5 TO Securities Purchase Agreement This Amendment No. 5 to Securities Purchase AGREEMENT is entered into as of December 30, 2016 (this ?Amendment?), among Cipher Pharmaceuticals INC., an Ontario corporation (the ?Issuer?), the Guarantors party hereto, Athyrium Opportunities II Acquisition LP, as a Purchaser, the other Purchasers party hereto (collectively, the ?Purchaser |
|
| December 21, 2016 |
Cipher Pharmaceuticals S-8 POS As filed with the Securities and Exchange Commission on December 20, 2016 Registration No. |
|
| December 21, 2016 |
Cipher Pharmaceuticals S-8 POS As filed with the Securities and Exchange Commission on December 20, 2016 Registration No. |
|
| December 21, 2016 |
Cipher Pharmaceuticals S-8 POS As filed with the Securities and Exchange Commission on December 20, 2016 Registration No. |
|
| December 9, 2016 |
Cipher Pharmaceuticals FORM 25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36734 Issuer: CIPHER PHARMACEUTICALS INC. Exchange: NASDAQ STOCK MARKET LLC (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/ |
|
| December 1, 2016 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2016 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 (905) 602 |
|
| December 1, 2016 |
Cipher Pharmaceuticals Announces Plans to Voluntarily Delist from NASDAQ Exhibit 99.1 Cipher Pharmaceuticals Announces Plans to Voluntarily Delist from NASDAQ MISSISSAUGA, ON, Nov. 29, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH; NASDAQ:CPHR) ("Cipher" or "the Company") today announced that its Board of Directors has approved the voluntary withdrawal of its common shares from NASDAQ and the voluntary de-registration of its common shares under the U.S. Securities |
|
| November 18, 2016 |
Exhibit 99.1 MATERIAL CHANGE REPORT 1. Name and Address of Reporting Issuer: Cipher Pharmaceuticals Inc. (the ?Corporation?) 2345 Argentia Road, Suite 100A Mississauga ON L5N 8K4 2. Date of Material Change: November 10, 2016. 3. News Release: A news release was issued and disseminated on November 11, 2016 through Canada Newswire. A copy of the news release is attached hereto as Schedule ?A?. 4. Su |
|
| November 18, 2016 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2016 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 (905) 602 |
|
| November 15, 2016 |
MANAGEMENT’S DISCUSSION AND ANALYSIS EX-99.1 2 v452863ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS September 30, 2016 The following is a discussion and analysis of the operating results and financial position of Cipher Pharmaceuticals Inc. and its subsidiaries (“Cipher” or “the Company") for the period ended September 30, 2016. This document should be read in conjunction with the unaudited interim condens |
|
| November 15, 2016 |
Form 52-109F2 - Certification of Interim Filings EX-99.3 4 v452863ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 Form 52-109F2 - Certification of Interim Filings I, Stephen Lemieux, Interim Chief Executive Officer and the Chief Financial Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Cipher Pharmaceuticals Inc. (the “issuer”) for t |
|
| November 15, 2016 |
Cipher Pharmaceuticals Inc. Interim Condensed Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2016 (Unaudited) Cipher Pharmaceuticals Inc. Interim Consolidated Statements of Financial Position As at September 30, 2016 and December 31, 2015 (in thousands of United States dollars - unaudited) Note 2016 2015 $ $ ASSETS Current assets Cash and cash equivalents 30,60 |
|
| November 15, 2016 |
Cipher Pharmaceuticals 6-K (Current Report of Foreign Issuer) 6-K 1 v4528636k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2016 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant’s name into English) 2345 Argentia Road, Suite 100A Mississauga, O |
|
| November 15, 2016 |
Form 52-109F2 - Certification of Interim Filings EX-99.4 5 v452863ex99-4.htm EXHIBIT 99.4 Exhibit 99.4 Form 52-109F2 - Certification of Interim Filings I, Stephen Lemieux, Interim Chief Executive Officer and the Chief Financial Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Cipher Pharmaceuticals Inc. (the “issuer”) for t |
|
| November 15, 2016 |
Cipher Pharmaceuticals Reports Q3 2016 Financial Results Exhibit 99.1 Cipher Pharmaceuticals Reports Q3 2016 Financial Results MISSISSAUGA, ON, Nov. 11, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three months ended September 30, 2016. Unless otherwise noted, all figures are in U.S. currency. Financial Highlights for Q3 2016 (all figures compare |
|
| November 15, 2016 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2016 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 (905) 602 |
|
| November 15, 2016 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2016 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 (905) 602 |
|
| November 15, 2016 |
Cipher Pharmaceuticals Announces Management Change Exhibit 99.1 Cipher Pharmaceuticals Announces Management Change MISSISSAUGA, ON, Nov. 11, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Stephen L. Lemieux, Chief Financial Officer and Secretary of the Company, has been named Interim Chief Executive Officer, replacing Shawn O'Brien, who is pursuing other opportunities. Cipher has co |
|
| September 30, 2016 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2016 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 (905) 60 |
|
| September 30, 2016 |
[Signature page to Amendment No. 4 to Securities Purchase Agreement] EX-99.1 2 ex991.htm MATERIAL CONTRACT Exhibit 99.1 AMENDMENT NO. 4 TO SECURITIES PURCHASE AGREEMENT This AMENDMENT NO. 4 TO SECURITIES PURCHASE AGREEMENT is entered into as of September 29, 2016 (this “Amendment”), among CIPHER PHARMACEUTICALS INC., an Ontario corporation (the “Issuer”), the Guarantors party hereto, ATHYRIUM OPPORTUNITIES II ACQUISITION LP, as a Purchaser, the other Purchasers par |
|
| September 1, 2016 |
Company also announces appointment of Dr. John Mull as Chair of the Board of Directors Exhibit 99.1 Cipher Pharmaceuticals appoints Stephen Lemieux as Chief Financial Officer Company also announces appointment of Dr. John Mull as Chair of the Board of Directors MISSISSAUGA, ON, Sept. 1, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Stephen L. Lemieux, BA, MMPA, CPA, has been appointed Chief Financial Officer and Secr |
|
| September 1, 2016 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2016 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 (905) 60 |
|
| August 10, 2016 |
EX-99.2 3 v446542ex99-2.htm Q1 CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.2 Cipher Pharmaceuticals Inc. Condensed Interim Consolidated Financial Statements For the Three and Six Months Ended June 30, 2016 (Unaudited) Cipher Pharmaceuticals Inc. Consolidated Balance Sheets As at June 30, 2016 and December 31, 2015 (in thousands of United States dollars - unaudited) Note 2016 201 |
|
| August 10, 2016 |
Form 52-109F2 - Certification of Interim Filings EX-99.3 4 v446542ex99-3.htm CEO CERTIFICATION Exhibit 99.3 Form 52-109F2 - Certification of Interim Filings I, Shawn Patrick O’Brien, President and Chief Executive Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Cipher Pharmaceuticals Inc. (the “issuer”) for the interim peri |
|
| August 10, 2016 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2016 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 (905) 602-5 |
|
| August 10, 2016 |
MANAGEMENT’S DISCUSSION AND ANALYSIS Exhibit 99.1 MANAGEMENT?S DISCUSSION AND ANALYSIS June 30, 2016 The following is a discussion and analysis of the operating results and financial position of Cipher Pharmaceuticals Inc. and its subsidiaries (?Cipher? or ?the Company") for the period ended June 30, 2016. This document should be read in conjunction with the unaudited condensed interim consolidated financial statements and the accomp |
|
| August 10, 2016 |
Form 52-109F2 - Certification of Interim Filings Exhibit 99.4 Form 52-109F2 - Certification of Interim Filings I, Norman Evans, Chief Financial Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Cipher Pharmaceuticals Inc. (the ?issuer?) for the interim period ended June 30, 2016. 2. No misrepresentations: Based on my knowled |
|
| August 10, 2016 |
Exhibit 99.1 Cipher Pharmaceuticals Reports Q2 2016 Results Highlighted by 32% Revenue Growth and $3.1 Million Cash from Operations MISSISSAUGA, ON, Aug. 10, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three months ended June 30, 2016. Unless otherwise noted, all figures are in U.S. curren |
|
| August 10, 2016 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2016 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 (905) 602-5 |
|
| August 9, 2016 |
Cipher Pharmaceuticals Inc. Announces Changes to its Board of Directors Exhibit 99.1 Cipher Pharmaceuticals Inc. Announces Changes to its Board of Directors MISSISSAUGA, ON, Aug. 9, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) ("Cipher") today announced certain changes to its board of directors (the "Board"). As previously disclosed, a special committee of the Board (the "Special Committee") was established to address the issues of the type referre |
|
| August 9, 2016 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) 6-K 1 cipher6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2016 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant’s name into English) 2345 Argentia Road, Suite 100A Mississauga, |
|
| August 5, 2016 |
Exhibit 99.1 Cipher Pharmaceuticals Announces Preliminary Q2 2016 Results Highlighted by 30+% Revenue Growth and $3.0+million Cash from Operations MISSISSAUGA, ON, Aug. 3, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced preliminary estimates of its financial results for the three months ended June 30, 2016. The complete financial statemen |
|
| August 5, 2016 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2016 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 (905) 602-5 |
|
| July 7, 2016 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2016 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 (905) 602-584 |
|
| July 7, 2016 |
Exhibit 99.1 Special Committee of Cipher Pharmaceuticals Responds to Early Warning Report Filed by 1207407 Ontario Limited MISSISSAUGA, ON, July 6, 2016 /CNW/ - A special committee (the "Special Committee") of the board of directors (the "Board") of Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher") responded today to an Early Warning Report (the "EWR") filed on July 5, 2016 by 1207407 |
|
| May 6, 2016 |
Exhibit 99.1 |
|
| May 6, 2016 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2016 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 (905) 602-5840 |
|
| May 6, 2016 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2016 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 (905) 602-5840 |
|
| May 6, 2016 |
Cipher Pharmaceuticals Reports Voting Results from Annual and Special Meeting of Shareholders Exhibit 99.1 Cipher Pharmaceuticals Reports Voting Results from Annual and Special Meeting of Shareholders MISSISSAUGA, ON, May 6, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced the voting results from its Annual and Special Meeting of Shareholders held on May 5, 2016 in Toronto, Ontario |
|
| May 6, 2016 |
Form 52-109F2 - Certification of Interim Filings EX-99.3 4 v439025ex99-3.htm CEO CERTIFICATION Exhibit 99.3 Form 52-109F2 - Certification of Interim Filings I, Shawn Patrick O’Brien, President and Chief Executive Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Cipher Pharmaceuticals Inc. (the “issuer”) for the interim peri |
|
| May 6, 2016 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2016 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 (905) 602-5840 |
|
| May 6, 2016 |
MANAGEMENT’S DISCUSSION AND ANALYSIS EX-99.1 2 v439025ex99-1.htm Q1 MANAGEMENT'S DISCUSSION AND ANALYSIS Exhibit 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS March 31, 2016 The following is a discussion and analysis of the operating results and financial position of Cipher Pharmaceuticals Inc. and its subsidiaries (“Cipher” or “the Company") for the period ended March 31, 2016. This document should be read in conjunction with the unaudi |
|
| May 6, 2016 |
Exhibit 99.2 Cipher Pharmaceuticals Inc. Condensed Interim Consolidated Financial Statements For the Three Months Ended March 31, 2016 Cipher Pharmaceuticals Inc. Consolidated Balance Sheets As at March 31, 2016 and December 31, 2015 (in thousands of United States dollars - unaudited) Note 2016 2015 $ $ ASSETS Current assets Cash and cash equivalents 28,802 27,182 Accounts receivable 15,573 16,303 |
|
| May 6, 2016 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) 6-K 1 v4390256k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2016 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant’s name into English) 2345 Argentia Road, Suite 100A Mississauga, O |
|
| May 6, 2016 |
Form 52-109F2 - Certification of Interim Filings EX-99.4 5 v439025ex99-4.htm CFO CERTIFICATION Exhibit 99.4 Form 52-109F2 - Certification of Interim Filings I, Norman Evans, Chief Financial Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Cipher Pharmaceuticals Inc. (the “issuer”) for the interim period ended March 31, 2016 |
|
| May 6, 2016 |
Exhibit 99.1 Cipher Pharmaceuticals Reports Q1 2016 Financial Results - Revenue increased 23% - Delivered on multiple commercial and regulatory milestones - Positive cash from operating activities of $1.4 million while investing in future growth MISSISSAUGA, ON, May 5, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced its financial and oper |
|
| April 22, 2016 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2016 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 (905) 602-58 |
|
| April 22, 2016 |
Cipher Pharmaceuticals Announces Retirement of CFO Norm Evans Exhibit 99.1 Cipher Pharmaceuticals Announces Retirement of CFO Norm Evans MISSISSAUGA, ON, April 22, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Norm Evans, Chief Financial Officer, will be retiring from the Company. Mr. Evans will remain in his current role to ensure a smooth transition of responsibilities, and the Company has |
|
| April 7, 2016 |
EX-99.2 3 v436320ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 |
|
| April 7, 2016 |
Exhibit 99.1 Cipher Pharmaceuticals Inc. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS and MANAGEMENT INFORMATION CIRCULAR March 31, 2016 Cipher Pharmaceuticals Inc. March 31, 2016 Dear Shareholders: It is my great pleasure to invite you to the Annual and Special Meeting (the ?Meeting?) of Cipher Pharmaceuticals Inc. (the ?Corporation?) to be held on Thursday, May 5, 2016 at the offices of |
|
| April 7, 2016 |
Cipher Pharmaceuticals 6-K (Current Report of Foreign Issuer) 6-K 1 v4363206k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2016 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant’s name into English) 2345 Argentia Road, Suite 100A Mississauga, Onta |
|
| April 4, 2016 |
AMENDMENT NO. 3 TO Securities Purchase Agreement Exhibit 99.1 AMENDMENT NO. 3 TO Securities Purchase Agreement This Amendment No. 3 to Securities Purchase AGREEMENT is entered into as of March 31, 2016 (this ?Amendment?), among Cipher Pharmaceuticals INC., an Ontario corporation (the ?Issuer?), the Guarantors party hereto, Athyrium Opportunities II Acquisition LP, as a Purchaser, the other Purchasers party hereto (collectively, the ?Purchasers?) |
|
| April 4, 2016 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2016 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 (905) 602-58 |
|
| March 30, 2016 |
Cipher Pharmaceuticals FORM 40-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 40-F ? Registration statement pursuant to Section 12 of the Securities Exchange Act of 1934 x Annual Report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2015 Commission File Number: 001-36734 CIPHER PHARMACEUTICALS INC. (Exact name of Registrant as speci |
|
| March 30, 2016 |
ANNUAL INFORMATION FORM FOR THE YEAR ENDED DECEMBER 31, 2015 March 30, 2016 Exhibit 99.1 ANNUAL INFORMATION FORM FOR THE YEAR ENDED DECEMBER 31, 2015 March 30, 2016 Cipher Pharmaceuticals Inc. 2015 Annual Information Form TABLE OF CONTENTS EXPLANATORY NOTES i Trademarks i Currency i Market Data i CAUTION REGARDING FORWARD-LOOKING STATEMENTS ii CORPORATE STRUCTURE 1 GENERAL DEVELOPMENT OF THE BUSINESS 1 History of the Company 1 Developments in 2015 2 THE BUSINESS 4 General |
|
| March 8, 2016 |
Cipher Pharmaceuticals Appoints Ralph Bohrer President & General Manager of U.S. Business Exhibit 99.1 Cipher Pharmaceuticals Appoints Ralph Bohrer President & General Manager of U.S. Business MISSISSAUGA, ON, March 4, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Ralph Bohrer has joined the Company in the position of President and General Manager of its U.S. subsidiary. Mr. Bohrer is a seasoned pharmaceutical executive |
|
| March 8, 2016 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2016 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 (905) 602-58 |
|
| February 24, 2016 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2016 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 (905) 602 |
|
| February 24, 2016 |
Cipher Pharmaceuticals Inc. Consolidated Financial Statements For the Year Ended December 31, 2015 EX-99.2 3 v432595ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Cipher Pharmaceuticals Inc. Consolidated Financial Statements For the Year Ended December 31, 2015 February 24, 2016 Independent Auditor’s Report To the Shareholders of Cipher Pharmaceuticals Inc. We have audited the accompanying consolidated financial statements of Cipher Pharmaceuticals Inc. and its subsidiaries, which comprise the consolidat |
|
| February 24, 2016 |
MANAGEMENT’S DISCUSSION AND ANALYSIS Exhibit 99.1 MANAGEMENT?S DISCUSSION AND ANALYSIS December 31, 2015 The following is a discussion and analysis of the operating results and financial position of Cipher Pharmaceuticals Inc. and its subsidiaries (?Cipher? or ?the Company") for the year ended December 31, 2015. This document should be read in conjunction with the audited consolidated financial statements and the accompanying notes, |
|
| February 24, 2016 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2016 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 (905) 602 |
|
| February 24, 2016 |
Exhibit 99.1 Cipher Pharmaceuticals Reports 2015 Financial Results Q4 revenue up 30%, Company significantly advances strategic plans to build a dermatology growth company MISSISSAUGA, ON, Feb. 24, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three and twelve months ended December 31, 2015. |
|
| February 12, 2016 |
CPHR / Cipher Pharmaceuticals, Inc. / 1207407 Ontario Ltd. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. )* Under the Securities Exchange Act of 1934 CIPHER PHARMACEUTICALS INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 17253X105 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| February 12, 2016 |
Exhibit 99.1 AGREEMENT OF JOINT FILING In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned hereby confirm the agreement by and among them to the joint filing on behalf of them of the Statement on Schedule 13G with respect to the securities of Cipher Pharmaceuticals Inc. and any and all amendments thereto and that this Agreement be included as an |
|
| January 4, 2016 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2016 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 (905) 602- |
|
| January 4, 2016 |
AMENDMENT NO. 2 TO Securities Purchase Agreement Exhibit 99.1 Execution Version AMENDMENT NO. 2 TO Securities Purchase Agreement This Amendment No. 2 to Securities Purchase AGREEMENT is entered into as of December 29, 2015 (this “Amendment”), among Cipher Pharmaceuticals INC., an Ontario corporation (the “Issuer”), the Guarantors party hereto, Athyrium Opportunities II Acquisition LP, as a Purchaser, the other Purchasers party hereto (collective |
|
| December 10, 2015 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2015 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 (905) 602 |
|
| December 10, 2015 |
– Will Represent Fourth Commercial Product in Cipher's Growing Canadian Dermatology Business – Exhibit 99.1 Cipher Receives Health Canada Approval of (Pr)Beteflam? ? Will Represent Fourth Commercial Product in Cipher's Growing Canadian Dermatology Business ? MISSISSAUGA, ON, Dec. 7, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Health Canada has approved PrBeteflam? (betamethasone valerate topical patch), a novel, patent-pro |
|
| November 4, 2015 |
Form 52-109F2 - Certification of Interim Filings EX-99.4 5 v423703ex99-4.htm EXHIBIT 99.4 Exhibit 99.4 Form 52-109F2 - Certification of Interim Filings I, Norman Evans, Chief Financial Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Cipher Pharmaceuticals Inc. (the “issuer”) for the interim period ended September 30, 2015. |
|
| November 4, 2015 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 4, 2015 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 (905) 6 |
|
| November 4, 2015 |
MANAGEMENT’S DISCUSSION AND ANALYSIS Exhibit 99.1 MANAGEMENT?S DISCUSSION AND ANALYSIS September 30, 2015 The following is a discussion and analysis of the operating results and financial position of Cipher Pharmaceuticals Inc. and its subsidiaries (?Cipher? or ?the Company") for the three and nine months ended September 30, 2015. This document should be read in conjunction with the unaudited condensed interim consolidated financial |
|
| November 4, 2015 |
Exhibit 99.1 Cipher Reports Third Quarter Results ? Quarter Highlighted by 28% Revenue Growth, $2.3 Million in Cash Flow from Operations and Strong Advancement of Pre-Commercial Portfolio ? MISSISSAUGA, ON, Nov. 4, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three and nine months ended Sep |
|
| November 4, 2015 |
EX-99.2 3 v423703ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Cipher Pharmaceuticals Inc. Condensed Interim Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2015 (Unaudited) Cipher Pharmaceuticals Inc. Consolidated Balance Sheets As at September 30, 2015 and December 31, 2014 (in thousands of United States dollars - unaudited) Note 2015 2014 $ $ ASSETS Current assets Cas |
|
| November 4, 2015 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2015 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 (905) 602 |
|
| November 4, 2015 |
Form 52-109F2 - Certification of Interim Filings EX-99.3 4 v423703ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 Form 52-109F2 - Certification of Interim Filings I, Shawn Patrick O’Brien, President and Chief Executive Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Cipher Pharmaceuticals Inc. (the “issuer”) for the interim period en |
|
| October 14, 2015 |
Exhibit 99.2 MATERIAL CHANGE REPORT 1. Name and Address of Reporting Issuer: Cipher Pharmaceuticals Inc. 2345 Argentia Road, Suite 100A Mississauga ON L5N 8K4 2. Date of Material Change: October 2, 2015. 3. News Release: A news release was issued and disseminated on October 5, 2015 through CNW. A copy of the news release is attached hereto as Schedule ?A?. 4. Summary of Material Change: On October |
|
| October 14, 2015 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 13, 2015 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 (905) 6 |
|
| October 14, 2015 |
Exhibit 99.1 EXECUTION COPY SETTLEMENT AGREEMENT This Settlement Agreement (including Exhibits A through C, the ?Agreement?) is made and entered into this 2nd day of October, 2015 (the ?Effective Date?), by and between, on the one hand, Cipher Pharmaceuticals Inc., Galephar Pharmaceutical Research, Inc., Ranbaxy Inc., and Ranbaxy Pharmaceuticals, Inc. (collectively, ?Plaintiffs?), and on the other |
|
| October 6, 2015 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 5, 2015 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 (905) 60 |
|
| October 6, 2015 |
Cipher announces settlement in patent litigation for Absorica® Exhibit 99.1 Cipher announces settlement in patent litigation for Absorica? MISSISSAUGA, ON, Oct. 5, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that the Company, along with its partners, Ranbaxy Pharmaceuticals, Inc. ("Ranbaxy"), a Sun Pharma Company, and Galephar Pharmaceutical Research, Inc. ("Galephar"), have entered into a Settle |
|
| October 6, 2015 |
AMENDMENT NO. 1 TO Securities Purchase Agreement Exhibit 99.1 Execution Version AMENDMENT NO. 1 TO Securities Purchase Agreement This Amendment No. 1 to Securities Purchase AGREEMENT is entered into as of September 30, 2015 (this ?Amendment?), among Cipher Pharmaceuticals INC., an Ontario corporation (the ?Issuer?), the Guarantors party hereto, Athyrium Opportunities II Acquisition LP, as a Purchaser, the other Purchasers party hereto (collectiv |
|
| October 6, 2015 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 6, 2015 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 (905) 60 |
|
| August 18, 2015 |
Form 52-109F2 - Certification of Interim Filings Exhibit 99.3 Form 52-109F2 - Certification of Interim Filings I, Shawn Patrick O?Brien, President and Chief Executive Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Cipher Pharmaceuticals Inc. (the ?issuer?) for the interim period ended June 30, 2015. 2. No misrepresentatio |
|
| August 18, 2015 |
Form 52-109F2 - Certification of Interim Filings Exhibit 99.4 Form 52-109F2 - Certification of Interim Filings I, Norman Evans, Chief Financial Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Cipher Pharmaceuticals Inc. (the ?issuer?) for the interim period ended June 30, 2015. 2. No misrepresentations: Based on my knowled |
|
| August 18, 2015 |
Cipher Pharmaceuticals FORM 6-K/A (Current Report of Foreign Issuer) 6-K/A 1 cipher6ka.htm FORM 6-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2015 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant’s name into English) 2345 Argentia Road, Suite 100A Missi |
|
| August 14, 2015 |
MANAGEMENT’S DISCUSSION AND ANALYSIS EX-99.1 2 v418241ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS June 30, 2015 The following is a discussion and analysis of the operating results and financial position of Cipher Pharmaceuticals Inc. (“Cipher” or “the Company") for the three and six months ended June 30, 2015. This document should be read in conjunction with the unaudited condensed interim financial stat |
|
| August 14, 2015 |
Exhibit 99.2 Cipher Pharmaceuticals Inc. Condensed Interim Consolidated Financial Statements For the Three and Six Months Ended June 30, 2015 (Unaudited) Cipher Pharmaceuticals Inc. Consolidated Balance Sheets As at June 30, 2015 and December 31, 2014 (in thousands of United States dollars - unaudited) Note 2015 2014 $ $ ASSETS Current assets Cash and cash equivalents 29,654 45,368 Accounts receiv |
|
| August 14, 2015 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2015 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 (905) 602-5 |
|
| August 14, 2015 |
Exhibit 99.1 Cipher Reports Financial and Operational Results for Q2 2015 ? Quarter Highlighted by Continued Solid Performance from Isotretinoin Products and Acquisition and Integration of Innocutis ? MISSISSAUGA, ON, Aug. 14, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three months ended |
|
| August 14, 2015 |
Form 52-109F2 - Certification of Interim Filings Exhibit 99.4 Form 52-109F2 - Certification of Interim Filings I, Norman Evans, Chief Financial Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Cipher Pharmaceuticals Inc. (the ?issuer?) for the interim period ended June 30, 2015. 2. No misrepresentations: Based on my knowled |
|
| August 14, 2015 |
Form 52-109F2 - Certification of Interim Filings Exhibit 99.3 Form 52-109F2 - Certification of Interim Filings I, Shawn Patrick O?Brien, President and Chief Executive Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Cipher Pharmaceuticals Inc. (the ?issuer?) for the interim period ended June 30, 2015. 2. No misrepresentatio |
|
| August 14, 2015 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2015 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 (905) 602-5 |
|
| August 4, 2015 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2015 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 (905) 602-5 |
|
| August 4, 2015 |
- Acceptance marks first regulatory filing with FDA since Absorica® in 2011 - Exhibit 99.1 Cipher Pharmaceuticals announces acceptance of 510(k) submission for Dermadexin? by FDA - Acceptance marks first regulatory filing with FDA since Absorica? in 2011 - MISSISSAUGA, ON, Aug. 4, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that it has received an Acceptance Review Notification for its 510(k) submission for Der |
|
| July 30, 2015 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2015 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 (905) 602-584 |
|
| July 30, 2015 |
Exhibit 99.1 Cipher Pharmaceuticals Announces Successful Completion of Second Phase III for Ozenoxacin - Company expects to submit Ozenoxacin for regulatory approval in Canada in the first quarter of 2016 - MISSISSAUGA, ON, July 30, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Ferrer International SA ("Ferrer") successfully comple |
|
| June 19, 2015 |
EX-4.1 2 a15-135411ex4d1.htm EX-4.1 Exhibit 4.1 Form 1 ARTICLES OF INCORPORATION Business STATUTS CONSTITUTIFS Corporations 1. The name of the corporation is: (Set out in BLOCK CAPITAL LETTERS) Act Dénomination sociale de la société : (Écrire en LETTRES MAJUSCULES SEULEMENT) CIPHER PHARMACEUTICALS INC. Formule 1 Loi sur les 2. The address of the registered office is: sociétés par Adresse du siége |
|
| June 19, 2015 |
As filed with the Securities and Exchange Commission on June 19, 2015 Registration No. |
|
| June 19, 2015 |
CIPHER PHARMACEUTICALS INC. BY-LAW 2 EX-4.3 3 a15-135411ex4d3.htm EX-4.3 Exhibit 4.3 CIPHER PHARMACEUTICALS INC. BY-LAW 2 BE IT ENACTED AND IT IS HEREBY ENACTED as a by-law of CIPHER PHARMACEUTICALS INC. (the “Corporation”) as follows: 1. The directors may and they are hereby authorized from time to time to, without authorization of the shareholders, (a) borrow money upon the credit of the Corporation; (b) limit or increase the amoun |
|
| June 19, 2015 |
CIPHER PHARMACEUTICALS INC. EMPLOYEE AND DIRECTOR SHARE PURCHASE PLAN Effective May 13, 2011 EX-99.1 6 a15-135411ex99d1.htm EX-99.1 Exhibit 99.1 CIPHER PHARMACEUTICALS INC. EMPLOYEE AND DIRECTOR SHARE PURCHASE PLAN Effective May 13, 2011 1. Purpose of the Plan 1.1 The purpose of the Plan is to encourage employees and directors of Cipher Pharmaceuticals Inc. (the “Corporation”) and its Subsidiaries to participate in the growth and development of the Corporation and its Subsidiaries by prov |
|
| June 19, 2015 |
CIPHER PHARMACEUTICALS INC. STOCK OPTION PLAN Exhibit 99.1 CIPHER PHARMACEUTICALS INC. STOCK OPTION PLAN 1. Interpretation In this Plan, the following terms shall have the following meanings: ?Administrators? means the Board or, if so designated by the Board to administer the Plan, the Compensation Committee of the Board or any other designated members of the Board; ?Associate? has the meaning assigned by the Securities Act (Ontario); ?Board? |
|
| June 19, 2015 |
S-8 1 a15-135411s8.htm S-8 As filed with the Securities and Exchange Commission on June 19, 2015 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Cipher Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Ontario, Canada Not Applicable (State or other jurisdiction o |
|
| June 19, 2015 |
As filed with the Securities and Exchange Commission on June 19, 2015 Registration No. |
|
| June 19, 2015 |
CIPHER PHARMACEUTICALS INC. PERFORMANCE AND RESTRICTED SHARE UNIT PLAN Exhibit 99.1 CIPHER PHARMACEUTICALS INC. PERFORMANCE AND RESTRICTED SHARE UNIT PLAN 1. PREAMBLE AND DEFINITIONS 1.1 Title and Conflict. The Plan described in this document shall be called the ?Performance and Restricted Share Unit Plan?. In the event of any conflict or inconsistency between the Plan described in this document and the Award Agreement (as defined below), the terms and conditions of |
|
| June 2, 2015 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2015 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 (905) 602-584 |
|
| June 2, 2015 |
- Company Adds Regulatory and Alliance Management Expertise to Support Expanded Product Portfolio - EX-99.1 2 ex991.htm NEWS RELEASE DATED JUNE 2, 2015 Exhibit 99.1 Cipher Pharmaceuticals Strengthens Leadership Team with Key Executive Appointments and Announces Launch of Vaniqa® in Canada - Company Adds Regulatory and Alliance Management Expertise to Support Expanded Product Portfolio - MISSISSAUGA, ON, June 2, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Com |
|
| May 18, 2015 |
Exhibit 99.1 Cipher Pharmaceuticals Inc. Voting Results (Section 11.3 of National Instrument 51-102) This report describes the matters voted upon and the outcome of the votes at the Annual and Special Meeting of Cipher Pharmaceuticals Inc. (the “Corporation”) held on May 13, 2015 Brief Description of Matters Voted Upon Outcome of the Vote Number of Votes Cast For Against Withheld In respect to the |
|
| May 18, 2015 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2015 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 5650 Tomken Road, Unit 16 Mississauga, Ontario L4W 4P1 (905) 602-5840 (Add |
|
| May 15, 2015 |
CIPHER PHARMACEUTICALS INC. BY-LAW 3 Exhibit 99.1 CIPHER PHARMACEUTICALS INC. BY-LAW 3 BE IT ENACTED AND IT IS HEREBY ENACTED as a by-law of Cipher Pharmaceuticals Inc. (the “Corporation”) as follows: 1. By-law 1 of the by-laws of the Corporation is hereby amended by adding thereto, following section 8 thereof, the following: “8.1 Nomination of Directors Subject only to the Act and the articles of the Corporation, only persons who ar |
|
| May 15, 2015 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2015 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 5650 Tomken Road, Unit 16 Mississauga, Ontario L4W 4P1 (905) 602-5840 (Add |
|
| May 15, 2015 |
CIPHER PHARMACEUTICALS INC. AMENDED AND RESTATED BY-LAW 1 Exhibit 99.2 CIPHER PHARMACEUTICALS INC. AMENDED AND RESTATED BY-LAW 1 A by-law relating generally to the conduct of the affairs of CIPHER PHARMACEUTICALS INC. BE IT ENACTED AND IT IS HEREBY ENACTED as a by-law of CIPHER PHARMACEUTICALS INC. (the ?Corporation?) as follows: INTERPRETATION 1. Definitions In this by-law and all other by-laws of the Corporation, unless the context otherwise specifies |
|
| May 14, 2015 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2015 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 5650 Tomken Road, Unit 16 Mississauga, Ontario L4W 4P1 (905) 602-5840 (Add |
|
| May 14, 2015 |
Cipher Pharmaceuticals Inc. Reports Voting Results from Annual and Special Meeting of Shareholders EX-99.1 2 ex991.htm NEWS RELEASE DATED MAY 14, 2015 Exhibit 99.1 Cipher Pharmaceuticals Inc. Reports Voting Results from Annual and Special Meeting of Shareholders MISSISSAUGA, ON, May 14, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced the voting results from its Annual and Special Meeti |
|
| May 13, 2015 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2015 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant’s name into English) 5650 Tomken Road, Unit 16 Mississauga, Ontario L4W 4P1 (905) 602-5840 (Add |
|
| May 13, 2015 |
Form 52-109F2 - Certification of Interim Filings EX-99.4 5 v410523ex99-4.htm EXHIBIT 99.4 Exhibit 99.4 Form 52-109F2 - Certification of Interim Filings I, Norman Evans, Chief Financial Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Cipher Pharmaceuticals Inc. (the “issuer”) for the interim period ended March 31, 2015. 2. |
|
| May 13, 2015 |
MANAGEMENT’S DISCUSSION AND ANALYSIS Exhibit 99.1 MANAGEMENT?S DISCUSSION AND ANALYSIS March 31, 2015 The following is a discussion and analysis of the operating results and financial position of Cipher Pharmaceuticals Inc. (?Cipher? or ?the Company") for the period ended March 31, 2015. This document should be read in conjunction with the unaudited condensed interim financial statements and the accompanying notes, which have been pr |
|
| May 13, 2015 |
– Company Achieves Significant Progress Across All Three Components of Growth Strategy – EX-99.1 2 ex991.htm NEWS RELEASE DATED MAY 13, 2015 Exhibit 99.1 Cipher Reports Financial and Operational Results for Q1 2015 – Company Achieves Significant Progress Across All Three Components of Growth Strategy – MISSISSAUGA, ON, May 13, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three |
|
| May 13, 2015 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2015 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 5650 Tomken Road, Unit 16 Mississauga, Ontario L4W 4P1 (905) 602-5840 (Add |
|
| May 13, 2015 |
Form 52-109F2 - Certification of Interim Filings EX-99.3 4 v410523ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 Form 52-109F2 - Certification of Interim Filings I, Shawn Patrick O’Brien, President and Chief Executive Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Cipher Pharmaceuticals Inc. (the “issuer”) for the interim period en |
|
| May 13, 2015 |
EX-99.2 3 v410523ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Cipher Pharmaceuticals Inc. Condensed Interim Financial Statements For the Three Months Ended March 31, 2015 (Unaudited) Cipher Pharmaceuticals Inc. Balance Sheets As at March 31, 2015 and December 31, 2014 (in thousands of Canadian dollars - unaudited) Note 2015 2014 $ $ ASSETS Current assets Cash and cash equivalents 47,070 52,631 Accounts re |
|
| May 8, 2015 |
CIPHER PHARMACEUTICALS INC. BUSINESS ACQUISITION REPORT FORM 51-102F4 EX-99.1 2 v409969ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CIPHER PHARMACEUTICALS INC. BUSINESS ACQUISITION REPORT FORM 51-102F4 ITEM 1. IDENTITY OF THE COMPANY 1.1 Name and Address of the Company Cipher Pharmaceuticals Inc. (the “Company”) 5650 Tomken Rd., Unit 16 Mississauga, Ontario L4W 4P1 1.2 Executive Officer The following is the name and business telephone number of a senior officer of the Compa |
|
| May 8, 2015 |
Cipher Pharmaceuticals 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2015 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 5650 Tomken Road, Unit 16 Mississauga, Ontario L4W 4P1 (905) 602-5840 (Add |
|
| May 8, 2015 |
Exhibit 99.2 Innocutis Holdings, LLC Report on Financial Statements For the years ended December 31, 2014 and 2013 Innocutis Holdings, LLC Contents Page Independent Auditor?s Report 1 - 2 Financial Statements Balance Sheets 3 Statements of Operations 4 Statements of Members? Equity 5 - 6 Statements of Cash Flows 7 Notes to Financial Statements 8 - 16 Supplemental Information Schedule 1 ? Cost of S |
|
| May 8, 2015 |
EX-99.3 4 v409969ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 Cipher Pharmaceuticals Inc. Pro Forma Consolidated Financial Statements (Unaudited) December 31, 2014 Cipher Pharmaceuticals Inc. Pro Forma Consolidated Balance Sheet (Unaudited) As at December 31, 2014 (in thousands of Canadian dollars) Cipher Pharmaceuticals Inc. Innocutis Holdings, LLC Pro Forma adjustments Note Pro Forma consolidated $ $ $ |
|
| May 7, 2015 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2015 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 5650 Tomken Road, Unit 16 Mississauga, Ontario L4W 4P1 (905) 602-5840 (Add |
|
| May 7, 2015 |
Cipher Pharmaceuticals Acquires Canadian Commercialization Rights to Vaniqa® and Actikerall® EX-99.1 2 ex991.htm NEWS RELEASE DATED MAY 6, 2015 Exhibit 99.1 Cipher Pharmaceuticals Acquires Canadian Commercialization Rights to Vaniqa® and Actikerall® MISSISSAUGA, ON, May 6, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it has strengthened its Canadian dermatology portfolio by acquiring the Canadian rights to Vaniqa® and Actikera |
|
| April 24, 2015 |
Exhibit 99.1 Cipher Pharmaceuticals announces outcome of Markman hearing in patent infringement suit for Absorica® MISSISSAUGA, ON, April 24, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that the Court has issued an opinion in the claim construction hearing (commonly referred to as a "Markman hearing") for the patent infringement suit |
|
| April 24, 2015 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2015 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 5650 Tomken Road, Unit 16 Mississauga, Ontario L4W 4P1 (905) 602-5840 (A |
|
| April 23, 2015 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2015 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 5650 Tomken Road, Unit 16 Mississauga, Ontario L4W 4P1 (905) 602-5840 (A |
|
| April 23, 2015 |
EX-99.3 4 v407996ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 Execution Version SECURITIES PURCHASE AGREEMENT Dated as of April 13, 2015 among CIPHER PHARMACEUTICALS INC. as the Issuer, THE SUBSIDIARIES OF THE ISSUER, as the Guarantors, ATHYRIUM OPPORTUNITIES II ACQUISITION LP as Purchaser THE OTHER PURCHASERS LISTED ON SCHEDULE I FROM TIME TO TIME and ATHYRIUM OPPORTUNITIES II ACQUISITION LP, as Collater |
|
| April 23, 2015 |
Exhibit 99.1 MATERIAL CHANGE REPORT 1. Name and Address of Reporting Issuer: Cipher Pharmaceuticals Inc. 5650 Tomken Rd., Unit 16 Mississauga, Ontario L4W 4P1 2. Date of Material Change: April 13, 2015. 3. News Release: A news release was issued and disseminated on April 13, 2015 through CNW. A copy of the news release is attached hereto as Schedule ?A?. 4. Summary of Material Change: On June Apri |
|
| April 23, 2015 |
MEMBERSHIP INTERESTS PURCHASE AGREEMENT Exhibit 99.2 Execution Version MEMBERSHIP INTERESTS PURCHASE AGREEMENT This Membership Interests Purchase Agreement (this ?Agreement?) is made and entered into on the 13th day of April, 2015 by and among the parties listed as ?Beneficial Sellers? on the signature pages and Annex A hereto (the ?Beneficial Sellers?), Innocutis Parent, LLC, a Delaware limited liability company (the ?Seller? and when |
|
| April 16, 2015 |
EX-99.1 2 v407231ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cipher Pharmaceuticals Inc. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS and MANAGEMENT INFORMATION CIRCULAR March 31, 2015 Cipher Pharmaceuticals Inc. March 31, 2015 Dear Shareholders: It is my great pleasure to invite you to the Annual and Special Meeting (the “Meeting”) of Cipher Pharmaceuticals Inc. (the “Corporation”) to be held on |
|
| April 16, 2015 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2015 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 5650 Tomken Road, Unit 16 Mississauga, Ontario L4W 4P1 (905) 602-5840 (A |
|
| April 16, 2015 |
Exhibit 99.2 |
|
| April 13, 2015 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2015 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 5650 Tomken Road, Unit 16 Mississauga, Ontario L4W 4P1 (905) 602-5840 (A |
|
| April 13, 2015 |
Cipher Pharmaceuticals announces U.S. commercial entry through acquisition of INNOCUTIS Exhibit 99.1 Cipher Pharmaceuticals announces U.S. commercial entry through acquisition of INNOCUTIS ? Accelerates development of a leading North American dermatology company ? Adds U.S. commercial infrastructure for our acquisition/in-licensing activities ? Raises US$100 million Senior Notes to finance acquisition and future growth MISSISSAUGA, ON, April 13, 2015 /CNW/ - Cipher Pharmaceuticals In |
|
| March 31, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 40-F ? Registration statement pursuant to Section 12 of the Securities Exchange Act of 1934 x Annual Report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2014 Commission File Number: 001-36734 CIPHER PHARMACEUTICALS INC. (Exact name of Registrant as speci |
|
| March 31, 2015 |
Exhibit 99.4 February 24, 2015 Consent of Independent Auditor We hereby consent to the incorporation by reference in the Annual Report on Form 40-F for the year ended December 31, 2014 of Cipher Pharmaceuticals Inc. of our report dated February 24, 2015, relating to the financial statements which appear in this Annual Report. /s/ PricewaterhouseCoopers LLP Chartered Professional Accountants, Licen |
|
| March 31, 2015 |
ANNUAL INFORMATION FORM FOR THE YEAR ENDED DECEMBER 31, 2014 March 31, 2015 EX-99.1 5 v406033ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ANNUAL INFORMATION FORM FOR THE YEAR ENDED DECEMBER 31, 2014 March 31, 2015 Cipher Pharmaceuticals Inc. 2014 Annual Information Form TABLE OF CONTENTS EXPLANATORY NOTES i Trademarks i Currency i Market Data i CAUTION REGARDING FORWARD-LOOKING STATEMENTS i CORPORATE STRUCTURE 1 GENERAL DEVELOPMENT OF THE BUSINESS 1 History of the Company 1 Devel |
|
| March 23, 2015 |
Cipher Pharmaceuticals FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2015 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant?s name into English) 5650 Tomken Road, Unit 16 Mississauga, Ontario L4W 4P1 (905) 602-5840 (A |
|
| March 23, 2015 |
Exhibit 99.1 Cipher Pharmaceuticals acquires Canadian rights to novel treatment for psoriasis and rheumatoid arthritis MISSISSAUGA, ON, March 23, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it has licensed the Canadian distribution rights to CF101, a novel chemical entity being developed by Can-Fite Biopharma ("Can-Fite") (NYSE MKT: C |
|
| February 26, 2015 |
CPHR / Cipher Pharmaceuticals, Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2015 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant’s name into English) 5650 Tomken Road, Unit 16 Mississauga, Ontario L4W 4P1 (905) 602-5840 |
|
| February 26, 2015 |
– Strengthens dermatology product pipeline with rights to three products – EX-99.1 2 ex991.htm NEWS RELEASE DATED FEBRUARY 26, 2015 Exhibit 99.1 Cipher Pharmaceuticals acquires three products from Astion Pharma – Strengthens dermatology product pipeline with rights to three products – MISSISSAUGA, ON, Feb. 26, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it has strengthened its product pipeline by acquiring t |
|
| February 25, 2015 |
CPHR / Cipher Pharmaceuticals, Inc. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2015 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant’s name into English) 5650 Tomken Road, Unit 16 Mississauga, Ontario L4W 4P1 (905) 602-5840 |
|
| February 25, 2015 |
CPHR / Cipher Pharmaceuticals, Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2015 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant’s name into English) 5650 Tomken Road, Unit 16 Mississauga, Ontario L4W 4P1 (905) 602-5840 |
|
| February 25, 2015 |
Cipher Pharmaceuticals Inc. Financial Statements For the Year Ended December 31, 2014 Exhibit 99.2 Cipher Pharmaceuticals Inc. Financial Statements For the Year Ended December 31, 2014 Independent Auditor’s Report To the Shareholders of Cipher Pharmaceuticals Inc. We have audited the accompanying financial statements of Cipher Pharmaceuticals Inc., which comprise the balance sheets as at December 31, 2014 and December 31, 2013 and the statements of earnings and comprehensive income |
|
| February 25, 2015 |
MANAGEMENT’S DISCUSSION AND ANALYSIS EX-99.1 2 v402754ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS December 31, 2014 The following is a discussion and analysis of the operating results and financial position of Cipher Pharmaceuticals Inc. (“Cipher” or “the Company") for the year ended December 31, 2014. This document should be read in conjunction with the audited financial statements and the accompanying |
|
| February 25, 2015 |
Cipher Reports Financial Results for Fiscal 2014 EX-99.1 2 ex991.htm NEWS RELEASE DATED FEBRUARY 25, 2015 Exhibit 99.1 Cipher Reports Financial Results for Fiscal 2014 MISSISSAUGA, ON, Feb. 25, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three and 12 months ended December 31, 2014. Financial & Operating Highlights · Record revenue of $32 |
|
| January 9, 2015 |
Cipher Pharmaceuticals acquires assets of Melanovus Oncology Inc. EX-99.1 2 ex991.htm NEWS RELEASE DATED JANUARY 9, 2015 Exhibit 99.1 Cipher Pharmaceuticals acquires assets of Melanovus Oncology Inc. MISSISSAUGA, ON, Jan. 9, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it has acquired the assets of Melanovus Oncology Inc. ("Melanovus"), a Hershey (Pennsylvania)-based life sciences company. The assets |
|
| January 9, 2015 |
CPHR / Cipher Pharmaceuticals, Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2015 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant’s name into English) 5650 Tomken Road, Unit 16 Mississauga, Ontario L4W 4P1 (905) 602-5840 |
|
| January 7, 2015 |
Exhibit 99.1 FOR IMMEDIATE RELEASE CIPHER PHARMACEUTICALS ACQUIRES CANADIAN COMMERCIALIZATION RIGHTS TO NOVEL ANTIBACTERIAL COMPOUND OZENOXACIN - Company expands Canadian dermatology portfolio – MISSISSAUGA, ONTARIO, January 7, 2015 — Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) (“Cipher” or “the Company”) today announced that it has licensed the Canadian rights to Ozenoxacin, a topical trea |
|
| January 7, 2015 |
CPHR / Cipher Pharmaceuticals, Inc. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2015 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant’s name into English) 5650 Tomken Road, Unit 16 Mississauga, Ontario L4W 4P1 (905) 602-5840 |
|
| December 18, 2014 |
CIPHER PHARMACEUTICALS INC. BY-LAW 3 Exhibit 99.2 CIPHER PHARMACEUTICALS INC. BY-LAW 3 BE IT ENACTED AND IT IS HEREBY ENACTED as a by-law of Cipher Pharmaceuticals Inc. (the “Corporation”) as follows: 1. By-law 1 of the by-laws of the Corporation is hereby amended by adding thereto, following section 8 thereof, the following: “8.1 Nomination of Directors Subject only to the Act and the articles of the Corporation, only persons who ar |
|
| December 18, 2014 |
CIPHER PHARMACEUTICALS INC. ANNOUNCES ADOPTION OF ADVANCE NOTICE BY-LAW EX-99.1 2 a14-264161ex99d1.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Toronto Stock Exchange Symbol: CPH NASDAQ Symbol: CPHR CIPHER PHARMACEUTICALS INC. ANNOUNCES ADOPTION OF ADVANCE NOTICE BY-LAW MISSISSAUGA, Ontario, December 18, 2014 — Cipher Pharmaceuticals Inc. (the “Company”) (TSX: CPH; NASDAQ: CPHR) (“Cipher” or “the Company”) announced today that its Board of Directors has approved a B |
|
| December 18, 2014 |
CPHR / Cipher Pharmaceuticals, Inc. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2014 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant’s name into English) 5650 Tomken Road, Unit 16 Mississauga, Ontario L4W 4P1 (905) 602-5840 |
|
| November 20, 2014 |
CIPHER PHARMACEUTICALS TO COMMENCE TRADING ON THE NASDAQ GLOBAL MARKET EX-99.1 2 a14-248941ex99d1.htm EX-99.1 Exhibit 99.1 INVESTOR RELATIONS CONTACT: Craig Armitage (416) 815-0700 ext. 278 [email protected] FOR IMMEDIATE RELEASE Toronto Stock Exchange Symbol: DND CIPHER PHARMACEUTICALS TO COMMENCE TRADING ON THE NASDAQ GLOBAL MARKET MISSISSAUGA, Ontario, November 20, 2014 — Cipher Pharmaceuticals Inc. (“Cipher” or the “Company”) (TSX:DND, NASDAQ:CPHR) today a |
|
| November 20, 2014 |
CPHR / Cipher Pharmaceuticals, Inc. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2014 Commission File Number 001-36734 CIPHER PHARMACEUTICALS INC. (Translation of registrant’s name into English) 5650 Tomken Road, Unit 16 Mississauga, Ontario L4W 4P1 (905) 602-5840 |
|
| November 7, 2014 |
Cipher Achieves Sales Milestone for Absorica Exhibit 99.37 99.37 News Release Dated January 21, 2014 Cipher Achieves Sales Milestone for Absorica Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, Jan. 21, 2014 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) (“Cipher” or “the Company”) today announced that its marketing partner for Absorica has reached a cumulative sales milestone in accordance with the parties’ commercial agreement, trigger |
|
| November 7, 2014 |
Exhibit 99.39 99.39 Notice of 2014 Annual Meeting Date and Record Date 100 University Avenue, 9th floor Toronto ON, M5J 2Y1 www.computershare.com Date: February 21, 2014 To: All Canadian Securities Regulatory Authorities Subject: CIPHER PHARMACEUTICALS INC. Dear Sirs: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Annual G |
|
| November 7, 2014 |
CIPHER MANAGEMENT’S DISCUSSION AND ANALYSIS December 31, 2013 Exhibit 99.41 99.41 Management’s Discussion and Analysis for the Fiscal Year Ended December 31, 2013 The following is a discussion and analysis of the operating results and financial position of Cipher Pharmaceuticals Inc. (“Cipher” or “the Company”) for the year ended December 31, 2013. This document should be read in conjunction with the audited financial statements and the accompanying notes, w |
|
| November 7, 2014 |
Cipher Pharmaceuticals Inc. Financial Statements For the Year Ended December 31, 2013 EX-99.80 81 a14-234141ex99d80.htm EX-99.80 Exhibit 99.80 99.80 Refiled 2013 Annual Financial Statements Cipher Pharmaceuticals Inc. Financial Statements For the Year Ended December 31, 2013 February 25, 2014 Independent Auditor’s Report To the Shareholders of Cipher Pharmaceuticals Inc. We have audited the accompanying financial statements of Cipher Pharmaceuticals Inc., which comprise the balance |
|
| November 7, 2014 |
Form 52-109F2 - Certification of Interim Filings EX-99.68 69 a14-234141ex99d68.htm EX-99.68 Exhibit 99.68 99.68 Canadian Form 52-109F2 — Certification of Interim Filings - CFO Form 52-109F2 - Certification of Interim Filings I, Norman Evans, Chief Financial Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Cipher Pharmaceuti |
|
| November 7, 2014 |
CIPHER REPORTS RECORD FINANCIAL RESULTS FOR 2013 Exhibit 99.42 99.42 News Release Dated February 26, 2014 INVESTOR RELATIONS CONTACT: Craig Armitage The Equicom Group Inc. (416) 815-0700 ext. 278 [email protected] FOR IMMEDIATE RELEASE Toronto Stock Exchange Symbol: DND CIPHER REPORTS RECORD FINANCIAL RESULTS FOR 2013 MISSISSAUGA, Ontario, February 26, 2014 - Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operati |
|
| November 7, 2014 |
Cipher Announces Change to Board of Directors EX-99.36 37 a14-234141ex99d36.htm EX-99.36 Exhibit 99.36 99.36 News Release Dated December 30, 2013 Cipher Announces Change to Board of Directors Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, Dec. 30, 2013 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) (“Cipher” or “the Company”) today announced that William (Bill) Garriock has resigned from his position of Chair of Cipher, effective Decembe |
|
| November 7, 2014 |
Exhibit 99.14 . MR SAM SAMPLE 123 SAMPLES STREET SAMPLETOWN SS X9X 9X9 00Y5LC Security Class COMMON 9th Floor, 100 University Avenue Toronto, Ontario M5J 2Y1 www.computershare.com Fold Fold CPUQC01.E.INT/000001/i1234 Intermediary X X X Voting Instruction Form ("VIF") - Annual and Special Meeting to be held on May 3, 2013 NON-REGISTERED (BENEFICIAL) SECURITYHOLDERS B1234567890 X X X Holder Account |
|
| November 7, 2014 |
Exhibit 99.13 99.13 Notice of 2013 Annual and Special Meeting CIPHER PHARMACEUTICALS INC. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 3, 2013 NOTICE IS HEREBY GIVEN that the Annual and Special Meeting (the “Meeting”) of the common shareholders of Cipher Pharmaceuticals Inc. (“Cipher” or the “Corporation”) will be held on Friday, May 3, 2013 at the offices of Goodmans LLP |
|
| November 7, 2014 |
Exhibit 99.12 99.12 Management Information Circular for the 2013 Annual and Special Meeting Cipher Pharmaceuticals Inc. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS and MANAGEMENT INFORMATION CIRCULAR March 29, 2013 CIPHER PHARMACEUTICALS INC. March 29, 2013 Dear Shareholders: It is my great pleasure to invite you to the Annual and Special Meeting (the “Meeting”) of Cipher Pharmaceuticals |
|
| November 7, 2014 |
EX-99.54 55 a14-234141ex99d54.htm EX-99.54 Exhibit 99.54 99.54 Interim Financial Statements as at and for the Three Months Ended March 31, 2014 Cipher Pharmaceuticals Inc. Condensed Interim Financial Statements For the Three Months Ended March 31, 2014 (Unaudited) Cipher Pharmaceuticals Inc. Balance Sheets As at March 31, 2014 and December 31, 2013 (in thousands of Canadian dollars - unaudited) Ma |
|
| November 7, 2014 |
Exhibit 99.58 99.58 News Release Dated May 2, 2014 INVESTOR RELATIONS CONTACT: Craig Armitage (416) 815-0700 ext. 278 [email protected] FOR IMMEDIATE RELEASE Toronto Stock Exchange Symbol: DND CIPHER REPORTS FINANCIAL RESULTS FOR Q1 2014 Company achieves ninth consecutive quarter of profitability MISSISSAUGA, Ontario, May 2, 2014 - Cipher Pharmaceuticals Inc. (TSX: DND) today announced its |
|
| November 7, 2014 |
CIPHER PHARMACEUTICALS APPOINTS SHAWN PATRICK O’BRIEN AS CEO Exhibit 99.63 99.63 News Release Dated June 26, 2014 INVESTOR RELATIONS CONTACT: Craig Armitage TMX Equicom (416) 815-0700 ext. 278 [email protected] FOR IMMEDIATE RELEASE Toronto Stock Exchange Symbol: DND CIPHER PHARMACEUTICALS APPOINTS SHAWN PATRICK O’BRIEN AS CEO MISSISSAUGA, Ontario, June 26, 2014 – Cipher Pharmaceuticals Inc. (TSX: DND) (“Cipher” or “the Company”) today announced that |
|
| November 7, 2014 |
Exhibit 99.66 99.66 MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2014 MANAGEMENT’S DISCUSSION AND ANALYSIS June 30, 2014 The following is a discussion and analysis of the operating results and financial position of Cipher Pharmaceuticals Inc. (“Cipher” or “the Company”) for the three months ended June 30, 2014. This document should be read in conjunction with th |
|
| November 7, 2014 |
EX-99.65 66 a14-234141ex99d65.htm EX-99.65 Exhibit 99.65 99.65 Interim Financial Statements as at and for the Three and Six Months Ended June 30, 2014 Cipher Pharmaceuticals Inc. Condensed Interim Financial Statements For the Three Months Ended June 30, 2014 (Unaudited) Cipher Pharmaceuticals Inc. Balance Sheets As at June 30, 2014 and December 31, 2013 (in thousands of Canadian dollars - unaudite |
|
| November 7, 2014 |
EX-99.52 53 a14-234141ex99d52.htm EX-99.52 Exhibit 99.52 99.52 Management Information Circular for the 2014 Annual Meeting Cipher Pharmaceuticals Inc. NOTICE OF ANNUAL MEETING OF SHAREHOLDERS and MANAGEMENT INFORMATION CIRCULAR March 31, 2014 CIPHER PHARMACEUTICALS INC. March 31, 2014 Dear Shareholders: It is my great pleasure to invite you to the Annual Meeting (the “Meeting”) of Cipher Pharmaceu |
|
| November 7, 2014 |
CIPHER APPOINTS THOMAS WELLNER TO BOARD Exhibit 99.46 99.46 News Release dated March 25, 2014 INVESTOR RELATIONS CONTACT: Craig Armitage TMX Equicom (416) 815-0700 ext. 278 [email protected] Stock Exchange Symbol: DND FOR IMMEDIATE RELEASE Toronto CIPHER APPOINTS THOMAS WELLNER TO BOARD MISSISSAUGA, Ontario, March 25, 2014 — Cipher Pharmaceuticals Inc. (TSX: DND) (“Cipher” or “the Company”) today announced that Thomas G. Wellner |
|
| November 7, 2014 |
EX-99.30 31 a14-234141ex99d30.htm EX-99.30 Exhibit 99.30 99.30 Material Change Report Dated September 20, 2013 MATERIAL CHANGE REPORT 1. Name and Address of Reporting Issuer Cipher Pharmaceuticals Inc. 5650 Tomken Rd., Unit 16 Mississauga, ON L4W 4P1 2. Date of Material Change September 19, 2013 3. News Release A news release was issued by Cipher Pharmaceuticals Inc. (the “Company”) on September 1 |
|
| November 7, 2014 |
Form 52-109F2 - Certification of Interim Filings Exhibit 99.19 99.19 Canadian Form 52-109F2 — Certification of Interim Filings - CEO Form 52-109F2 - Certification of Interim Filings I, Larry Andrews, President and Chief Executive Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Cipher Pharmaceuticals Inc. (the “issuer”) for |
|
| November 7, 2014 |
CIPHER MANAGEMENT’S DISCUSSION AND ANALYSIS December 31, 2012 Exhibit 99.03 99.03 Management’s Discussion and Analysis for Fiscal Year Ended December 31, 2012 CIPHER MANAGEMENT’S DISCUSSION AND ANALYSIS December 31, 2012 The following is a discussion and analysis of the operating results and financial position of Cipher Pharmaceuticals Inc. (“Cipher” or “the Company”) for the year ended December 31, 2012. This document should be read in conjunction with the |
|
| November 7, 2014 |
Cipher Pharmaceuticals Inc. Financial Statements For the Year Ended December 31, 2012 Exhibit 99.02 99.02 Audited Financial Statements as of and for the Fiscal Year Ended December 31, 2012 Cipher Pharmaceuticals Inc. Financial Statements For the Year Ended December 31, 2012 Cipher Pharmaceuticals Inc. Balance Sheets As at December 31, 2012 and December 31, 2011 (in thousands of Canadian dollars) December 31, December 31, Note 2012 2011 $ $ ASSETS Current assets Cash and cash equiva |
|
| November 7, 2014 |
Exhibit 99.15 99.15 Certificate Re: Dissemination to Shareholders RECEIVED APR 15 2013 100 University Avenue 11th Floor Toronto, Ontario M5J 2Y1 Norman Evans Cipher Pharmaceuticals Inc 5650 Tomken Road Unit 16 Mississauga, ON L4W 4P1 April 9, 2013 RE: Confirmation of Mailing Dear Client: Please find enclosed our sworn Affidavit of mailing with exhibits confirming proxy materials mailed to your hol |
|
| November 7, 2014 |
Form 52-109F2 - Certification of Interim Filings Exhibit 99.27 99.27 Canadian Form 52-109F2 — Certification of Interim Filings - CFO Form 52-109F2 - Certification of Interim Filings I, Norman Evans, Chief Financial Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Cipher Pharmaceuticals Inc. (the “issuer”) for the interim pe |
|
| November 7, 2014 |
FORM 52-109F1R CERTIFICATION OF REFILED ANNUAL FILINGS Exhibit 99.77 FORM 52-109F1R CERTIFICATION OF REFILED ANNUAL FILINGS This certificate is being filed on the same date that Cipher Pharmaceuticals Inc. (the “issuer”) has refiled the annual financial statements of the issuer for the financial year ended December 31, 2012. I, Shawn Patrick O’Brien, President and Chief Executive Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review |
|
| November 7, 2014 |
CIPHER REPORTS FINANCIAL RESULTS FOR Q2 2014 EX-99.69 70 a14-234141ex99d69.htm EX-99.69 Exhibit 99.69 99.69 News Release Dated July 30, 2014 INVESTOR RELATIONS CONTACT: Craig Armitage (416) 815-0700 ext. 278 [email protected] FOR IMMEDIATE RELEASE Toronto Stock Exchange Symbol: DND CIPHER REPORTS FINANCIAL RESULTS FOR Q2 2014 MISSISSAUGA, Ontario, July 30, 2014 - Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and |
|
| November 7, 2014 |
CIPHER PHARMACEUTICALS INC. TO PRESENT AT THE 2014 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE Exhibit 99.59 99.59 News Release Dated May 5, 2014 INVESTOR RELATIONS CONTACT: Craig Armitage TMX Equicom (416) 815-0700 ext. 278 [email protected] CIPHER PHARMACEUTICALS INC. TO PRESENT AT THE 2014 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE MISSISSAUGA, Ontario, May XX, 2014 — Cipher Pharmaceuticals Inc. (TSX: DND) (“Cipher” or “the Company”) today announced that Norm Evans, Chief F |
|
| November 7, 2014 |
Form 52-109F2 - Certification of Interim Filings Exhibit 99.57 99.57 Canadian Form 52-109F2 — Certification of Interim Filings — CFO Form 52-109F2 - Certification of Interim Filings I, Norman Evans, Chief Financial Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Cipher Pharmaceuticals Inc. (the “issuer”) for the interim pe |
|
| November 7, 2014 |
Exhibit 99.51 Holder Account Number Security Class 8th Floor, 100 University Avenue Toronto, Ontario M5J 2Y1 www.computershare.com Form of Proxy - Annual Meeting to be held on May 2, 2014 19FE14068011DOB This Form of Proxy is solicited by and on behalf of Management of Cipher Pharmaceuticals Inc. (the “Corporation”) Fold Fold 1-866-732-VOTE (8683) Toll Free CONTROL NUMBER VOTE USING THE TELEPHONE, |
|
| November 7, 2014 |
Exhibit 99.47 99.47 Annual Information Form for the Fiscal Year Ended December 31, 2013 CIPHER PHARMACEUTICALS INC. ANNUAL INFORMATION FORM FOR THE YEAR ENDED DECEMBER 31, 2013 March 28, 2014 Cipher Pharmaceuticals Inc. 2013 Annual Information Form TABLE OF CONTENTS CAUTION REGARDING FORWARD-LOOKING STATEMENTS I CORPORATE STRUCTURE 1 GENERAL DEVELOPMENT OF THE BUSINESS 1 HISTORY OF THE COMPANY 1 R |
|
| November 7, 2014 |
Form 52-109F2 - Certification of Interim Filings EX-99.34 35 a14-234141ex99d34.htm EX-99.34 Exhibit 99.34 99.34 Canadian Form 52-109F2 — Certification of Interim Filings - CFO Form 52-109F2 - Certification of Interim Filings I, Norman Evans, Chief Financial Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Cipher Pharmaceuti |
|
| November 7, 2014 |
EX-99.28 29 a14-234141ex99d28.htm EX-99.28 Exhibit 99.28 99.28 News Release Dated July 31, 2013 INVESTOR RELATIONS CONTACT: Craig Armitage TMX Equicom (416) 815-0700 ext. 278 [email protected] FOR IMMEDIATE RELEASE Toronto Stock Exchange Symbol: DND CIPHER REPORTS RECORD FINANCIAL RESULTS FOR Q2 2013 Revenue increases to $5.5 million; Company records earnings per share of $0.13 MISSISSAUGA, |
|
| November 7, 2014 |
99.09 Cover Letter dated March 25, 2013 EX-99.09 10 a14-234141ex99d09.htm EX-99.09 Exhibit 99.09 99.09 Cover Letter dated March 25, 2013 Dear Sirs/Mesdames: Re: Cipher Pharmaceuticals Inc. (the “Corporation”) Annual Information Form filed on March 18, 2013 The purpose of this cover letter is to describe certain errors contained in the Corporation’s Annual Information Form that was filed on SEDAR on March 18, 2013. The typographical erro |
|
| November 7, 2014 |
Exhibit 99.01 99.01 Notice of 2013 Annual Meeting Date and Record Date 100 University Avenue, 9th floor Date: February 19, 2013 Toronto ON, M5J 2Y1 www.computershare.com To: All Canadian Securities Regulatory Authorities Subject: CIPHER PHARMACEUTICALS INC. Dear Sirs: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Annual G |
|
| November 7, 2014 |
Exhibit 99.60 99.60 Report of Voting Results of 2014 Annual Meeting Cipher Pharmaceuticals Inc. Voting Results (Section 11.3 of National Instrument 51-102) This report describes the matters voted upon and the outcome of the votes at the Annual and Special Meeting of Cipher Pharmaceuticals Inc. (the “Corporation”) held on May 2, 2014 Number Brief Description of Outcome of Votes Cast Matters Voted U |
|
| November 7, 2014 |
Exhibit 99.64 99.64 News Release Dated July 24, 2014 INVESTOR RELATIONS CONTACT: Craig Armitage (416) 815-0700 ext. 278 [email protected] FOR IMMEDIATE RELEASE Toronto Stock Exchange Symbol: DND CIPHER PHARMACEUTICALS AND RANBAXY ANNOUNCE DISTRIBUTION AGREEMENT FOR ISOTRETINOIN PRODUCT IN BRAZIL MISSISSAUGA, Ontario, July 24, 2014 – Cipher Pharmaceuticals Inc. (TSX: DND) today announced it |
|
| November 7, 2014 |
EX-99.79 80 a14-234141ex99d79.htm EX-99.79 Exhibit 99.79 November 5, 2014 Re: Financial Statements for the Year Ended December 31, 2013 Cipher Pharmaceuticals Inc. (the “Company) is applying for a listing of its common shares on NASDAQ as has been publicly disclosed. In connection with the listing application and the filing by the Company of a Form 40-F with the United States Securities and Exchan |
|
| November 7, 2014 |
EX-99.06 7 a14-234141ex99d06.htm EX-99.06 Exhibit 99.06 99.06 Revised Annual Information Form for the Fiscal Year Ended December 31, 2012 CIPHER PHARMACEUTICALS INC. ANNUAL INFORMATION FORM FOR THE YEAR ENDED DECEMBER 31, 2012 March 25, 2013 Cipher Pharmaceuticals Inc. 2012 Annual Information Form TABLE OF CONTENTS CAUTION REGARDING FORWARD-LOOKING STATEMENTS I CORPORATE STRUCTURE 1 GENERAL DEVELO |
|
| November 7, 2014 |
Form 52-109F2 - Certification of Interim Filings Exhibit 99.72 99.72 Canadian Form 52-109F2 — Certification of Interim Filings - CEO Form 52-109F2 - Certification of Interim Filings I, Shawn Patrick O’Brien, President and Chief Executive Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Cipher Pharmaceuticals Inc. (the “issu |
|
| November 7, 2014 |
Form 52-109F1 Certification of Annual Filings Exhibit 99.49 99.49 Canadian Form 52-109F1 Certification of Annual Filings - CFO Form 52-109F1 Certification of Annual Filings I, Norman Evans, Chief Financial Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorporated by |
|
| November 7, 2014 |
EX-99.10 11 a14-234141ex99d10.htm EX-99.10 Exhibit 99.10 GROWTH TOMORROW. Cipher is investing in ongoing growth Building on the strong financial performance of 2012, we are concentrating on three primary strategies to achieve growth in 2013 and beyond: GROWING OUR CURRENTLY MARKETED PRODUCTS A primary driver in 2013 will be increased aggregate sales of our current products, most significantly deri |
|
| November 7, 2014 |
CIPHER REPORTS RECORD FINANCIAL RESULTS FOR 2012 Exhibit 99.04 99.04 News Release Dated March 1, 2013 INVESTOR RELATIONS CONTACT: Craig Armitage The Equicom Group Inc. (416) 815-0700 ext. 278 [email protected] FOR IMMEDIATE RELEASE Toronto Stock Exchange Symbol: DND CIPHER REPORTS RECORD FINANCIAL RESULTS FOR 2012 - Revenue increases 137%, Company records earnings of $0.10 per share - MISSISSAUGA, Ontario, March 1, 2013 - Cipher Pharmaceu |
|
| November 7, 2014 |
EX-99.11 12 a14-234141ex99d11.htm EX-99.11 Exhibit 99.11 MR SAM SAMPLE 123 SAMPLES STREET SAMPLETOWN SS X9X 9X9 00Y5JB Security Class COMMON SHARES C1234567890 X X X Holder Account Number 9th Floor, 100 University Avenue Toronto, Ontario M5J 2Y1 www.computershare.com Fold Fold CPUQC01.E.INT/000001/i1234 Form of Proxy - Annual and Special Meeting to be held on May 3, 2013 This Form of Proxy is soli |
|
| November 7, 2014 |
Form 52-109F2 - Certification of Interim Filings Exhibit 99.20 99.20 Canadian Form 52-109F2 — Certification of Interim Filings - CFO Form 52-109F2 - Certification of Interim Filings I, Norman Evans, Chief Financial Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Cipher Pharmaceuticals Inc. (the “issuer”) for the interim pe |
|
| November 7, 2014 |
Exhibit 99.21 99.21 News Release Dated May 3, 2013 INVESTOR RELATIONS CONTACT: Craig Armitage The Equicom Group Inc. (416) 815-0700 ext. 278 [email protected] FOR IMMEDIATE RELEASE Toronto Stock Exchange Symbol: DND CIPHER REPORTS RECORD FINANCIAL RESULTS FOR Q1 2013 - Revenue increases 82%, Company records earnings of $0.06 per share - MISSISSAUGA, Ontario, May 3, 2013 - Cipher Pharmaceuti |
|
| November 7, 2014 |
Exhibit 99.24 99.24 Interim Financial Statements as at and for the Three and Six Months Ended June 30, 2013 Cipher Pharmaceuticals Inc. Condensed Interim Financial Statements For the Three Months Ended June 30, 2013 (Unaudited) Cipher Pharmaceuticals Inc. Balance Sheets As at June 30, 2013 and December 31, 2012 (in thousands of Canadian dollars - unaudited) June 30, December 31, Note 2013 2012 $ $ |
|
| November 7, 2014 |
Form 52-109F2 - Certification of Interim Filings Exhibit 99.26 99.26 Canadian Form 52-109F2 — Certification of Interim Filings - CEO Form 52-109F2 - Certification of Interim Filings I, Larry Andrews, President and Chief Executive Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Cipher Pharmaceuticals Inc. (the “issuer”) for |
|
| November 7, 2014 |
Exhibit 99.31 99.31 Interim Financial Statements as at and for the Three and Nine Months Ended September 30, 2013 Cipher Pharmaceuticals Inc. Condensed Interim Financial Statements For the Three Months Ended September 30, 2013 (Unaudited) Cipher Pharmaceuticals Inc. Balance Sheets As at September 30, 2013 and December 31, 2012 (in thousands of Canadian dollars - unaudited) September 30, December 3 |
|
| November 7, 2014 |
Form 52-109F2 - Certification of Interim Filings Exhibit 99.33 99.33 Canadian Form 52-109F2 — Certification of Interim Filings - CEO Form 52-109F2 - Certification of Interim Filings I, Larry Andrews, President and Chief Executive Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Cipher Pharmaceuticals Inc. (the “issuer”) for |
|
| November 7, 2014 |
Exhibit 99.50 IN 10 YEARS WE HAVE ACCOMPLISHED A LOT Cipher recently celebrated its 10-year anniversary as a public company. During this period, the business has been transformed, from a development-stage company to a profitable, commercial specialty pharmaceutical company with 3 products on the market, 5 marketing partnerships, 5 separate revenue streams, a commercial footprint in Canada, and a s |
|
| November 7, 2014 |
CPHR / Cipher Pharmaceuticals, Inc. F-X - - F-X UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-X APPOINTMENT OF AGENT FOR SERVICE OF PROCESS AND UNDERTAKING A. Name of issuer or person filing (“Filer”): Cipher Pharmaceuticals Inc. B. (1) This is [check one] x an original filing for the Filer o an amended filing for the Filer (2) Check the following box if you are filing the Form F-X in paper in accordance with Re |
|
| November 7, 2014 |
FORM 52-109F1R CERTIFICATION OF REFILED ANNUAL FILINGS Exhibit 99.81 FORM 52-109F1R CERTIFICATION OF REFILED ANNUAL FILINGS This certificate is being filed on the same date that Cipher Pharmaceuticals Inc. (the “issuer”) has refiled the annual financial statements of the issuer for the financial year ended December 31, 2013. I, Shawn Patrick O’Brien, President and Chief Executive Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review |
|
| November 7, 2014 |
Exhibit 99.75 November 5, 2014 Re: Financial Statements for the Year Ended December 31, 2012 Cipher Pharmaceuticals Inc. (the “Company) is applying for a listing of its common shares on NASDAQ as has been publicly disclosed. In connection with the listing application and the filing by the Company of a Form 40-F with the United States Securities and Exchange Commission (the “SEC”), pursuant to the |
|
| November 7, 2014 |
Exhibit 99.70 99.70 Interim Financial Statements as at and for the Three and Nine Months Ended September 30, 2014 Cipher Pharmaceuticals Inc. Condensed Interim Financial Statements For the Three and Nine Month Periods Ended September 30, 2014 (Unaudited) Cipher Pharmaceuticals Inc. Balance Sheets As at September 30, 2014 and December 31, 2013 (in thousands of Canadian dollars - unaudited) Septembe |
|
| November 7, 2014 |
EX-99.62 63 a14-234141ex99d62.htm EX-99.62 Exhibit 99.62 99.62 Material Change Report Dated June 26, 2014 MATERIAL CHANGE REPORT 1. Name and Address of Reporting Issuer: Cipher Pharmaceuticals Inc. 5650 Tomken Rd., Unit 16 Mississauga, Ontario L4W 4P1 2. Date of Material Change: June 26, 2014. 3. News Release: A news release was issued and disseminated on June 26, 2014 through Canada News Wire. A |
|
| November 7, 2014 |
CIPHER MANAGEMENT’S DISCUSSION AND ANALYSIS March 31, 2014 EX-99.55 56 a14-234141ex99d55.htm EX-99.55 Exhibit 99.55 99.55 Management’s Discussion and Analysis for the Three Months Ended March 31, 2014 The following is a discussion and analysis of the operating results and financial position of Cipher Pharmaceuticals Inc. (“Cipher” or “the Company”) for the three months ended March 31, 2014. This document should be read in conjunction with the unaudited co |
|
| November 7, 2014 |
Form 52-109F1 Certification of Annual Filings EX-99.48 49 a14-234141ex99d48.htm EX-99.48 Exhibit 99.48 99.48 Canadian Form 52-109F1 — Certification of Annual Filings - CEO Form 52-109F1 Certification of Annual Filings I, Larry Andrews, President and Chief Executive Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certa |
|
| November 7, 2014 |
Cipher’s Partner Ranbaxy receives Paragraph IV Certification Exhibit 99.29 99.29 News Release Dated September 19, 2013 Cipher’s Partner Ranbaxy receives Paragraph IV Certification Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, Sept. 19, 2013 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) (“Cipher”) today announced that its sales and distribution partner, Ranbaxy Laboratories Inc. (“Ranbaxy”) has received a Paragraph IV Certification Notice of filing fr |
|
| November 7, 2014 |
Cipher introduces Epuris™ (isotretinoin) capsules in Canadian market EX-99.23 24 a14-234141ex99d23.htm EX-99.23 Exhibit 99.23 99.23 News Release Dated July 2, 2013 Cipher introduces Epuris™ (isotretinoin) capsules in Canadian market Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, July 2, 2013 /CNW/ - At the 88th annual Canadian Dermatology Association Conference held in Quebec City over the July 1st weekend, Cipher Pharmaceuticals Inc. (TSX: DND) (“Cipher”) ann |
|
| November 7, 2014 |
CIPHER MANAGEMENT’S DISCUSSION AND ANALYSIS March 31, 2013 Exhibit 99.18 99.18 Management’s Discussion and Analysis for the Three Months Ended March 31, 2013 CIPHER MANAGEMENT’S DISCUSSION AND ANALYSIS March 31, 2013 The following is a discussion and analysis of the operating results and financial position of Cipher Pharmaceuticals Inc. (“Cipher” or “the Company”) for the three months ended March 31, 2013. This document should be read in conjunction with |
|
| November 7, 2014 |
FORM 13-502F1 CLASS 1 REPORTING ISSUERS — PARTICIPATION FEE EX-99.05 6 a14-234141ex99d05.htm EX-99.05 Exhibit 99.05 99.05 ON Form 13-502F1 (Class 1 Reporting Issuers) FORM 13-502F1 CLASS 1 REPORTING ISSUERS — PARTICIPATION FEE Reporting Issuer Name: Cipher Pharmaceuticals Inc. End date of last completed fiscal year: December 31, 2012 <>: Total number of securities of a class or series outstanding as at the (i) end of the issuer’s last completed fiscal year |
|
| November 7, 2014 |
CIPHER PHARMACEUTICALS COMPLETES DISTRIBUTION AND SUPPLY AGREEMENT FOR ISOTRETINOIN PRODUCT IN CHILE Exhibit 99.61 99.61 News Release Dated June 18, 2014 INVESTOR RELATIONS CONTACT: Craig Armitage (416) 815-0700 ext. 278 [email protected] FOR IMMEDIATE RELEASE Toronto Stock Exchange Symbol: DND CIPHER PHARMACEUTICALS COMPLETES DISTRIBUTION AND SUPPLY AGREEMENT FOR ISOTRETINOIN PRODUCT IN CHILE MISSISSAUGA, Ontario, June 18, 2014 - Cipher Pharmaceuticals Inc. (TSX: DND) today announced it h |
|
| November 7, 2014 |
Form 52-109F2 - Certification of Interim Filings EX-99.73 74 a14-234141ex99d73.htm EX-99.73 Exhibit 99.73 99.73 Canadian Form 52-109F2 — Certification of Interim Filings - CFO Form 52-109F2 - Certification of Interim Filings I, Norman Evans, Chief Financial Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Cipher Pharmaceuti |
|
| November 7, 2014 |
Cipher Pharmaceuticals Inc. Financial Statements For the Year Ended December 31, 2012 EX-99.76 77 a14-234141ex99d76.htm EX-99.76 Exhibit 99.76 Exhibit 99.76 - Refiled 2012 Annual Financial Statements Cipher Pharmaceuticals Inc. Financial Statements For the Year Ended December 31, 2012 February 28, 2013 Independent Auditor’s Report To the Shareholders of Cipher Pharmaceuticals Inc. We have audited the accompanying financial statements of Cipher Pharmaceuticals Inc., which comprise t |
|
| November 7, 2014 |
FORM 52-109F1R CERTIFICATION OF REFILED ANNUAL FILINGS Exhibit 99.78 FORM 52-109F1R CERTIFICATION OF REFILED ANNUAL FILINGS This certificate is being filed on the same date that Cipher Pharmaceuticals Inc. (the “issuer”) has refiled the annual financial statements of the issuer for the financial year ended December 31, 2012. I, Norman Evans, Chief Financial Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the A |
|
| November 7, 2014 |
Cipher Pharmaceuticals Inc. Financial Statements For the Three Months Ended March 31, 2013 Exhibit 99.17 99.17 Interim Financial Statements as at and for the Three Months Ended March 31, 2013 Cipher Pharmaceuticals Inc. Financial Statements For the Three Months Ended March 31, 2013 (Unaudited) Cipher Pharmaceuticals Inc. Balance Sheets As at March 31, 2013 and December 31, 2012 (in thousands of Canadian dollars - unaudited) March 31, December 31, Note 2013 2012 $ $ ASSETS Current assets |
|
| November 7, 2014 |
Exhibit 99.22 99.22 Report of Voting Results of 2013 Annual Meeting Cipher Pharmaceuticals Inc. Voting Results (Section 11.3 of National Instrument 51-102) This report describes the matters voted upon and the outcome of the votes at the Annual and Special Meeting of Cipher Pharmaceuticals Inc. (the “Corporation”) held on May 3, 2013 Number Brief Description of Outcome of Votes Cast Matters Voted U |
|
| November 7, 2014 |
CIPHER MANAGEMENT’S DISCUSSION AND ANALYSIS September 30, 2013 Exhibit 99.32 99.32 Management’s Discussion and Analysis for the Three and Nine Months Ended September 30, 2013 The following is a discussion and analysis of the operating results and financial position of Cipher Pharmaceuticals Inc. (“Cipher” or “the Company”) for the three months ended September 30, 2013. This document should be read in conjunction with the unaudited interim financial statements |
|
| November 7, 2014 |
CIPHER APPOINTS GERALD MCDOLE AS CHAIR OF THE BOARD EX-99.38 39 a14-234141ex99d38.htm EX-99.38 Exhibit 99.38 99.38 NEWS RELEASE DATED FEBRUARY 5, 2014 CIPHER APPOINTS GERALD MCDOLE AS CHAIR OF THE BOARD Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, Feb. 5, 2014 - Cipher Pharmaceuticals Inc. (TSX: DND) (“Cipher” or “the Company”) today announced that Gerald (Gerry) McDole has been appointed as Chair of the Board of Directors of the Company eff |
|
| November 7, 2014 |
Cipher Pharmaceuticals Inc. Financial Statements For the Year Ended December 31, 2013 EX-99.40 41 a14-234141ex99d40.htm EX-99.40 Exhibit 99.40 99.40 Audited Financial Statements as of and for the Fiscal Year Ended December 31, 2013 Cipher Pharmaceuticals Inc. Financial Statements For the Year Ended December 31, 2013 Cipher Pharmaceuticals Inc. Balance Sheets As at December 31, 2013 and December 31, 2012 (in thousands of Canadian dollars) December 31, December 31, Note 2013 2012 $ $ |
|
| November 7, 2014 |
FORM 13-502F1 CLASS 1 REPORTING ISSUERS — PARTICIPATION FEE Exhibit 99.43 99.43 ON Form 13-502F1 (Class 1 Reporting Issuers - Participation Fee) April 1, 2013 Unofficial Consolidation — Rule 13-502 Fees [Form 13-502F1] FORM 13-502F1 CLASS 1 REPORTING ISSUERS — PARTICIPATION FEE Reporting Issuer Name: Cipher Pharmaceuticals Inc. End date of last completed fiscal year: December 31, 2013 End date of reference fiscal year: December 31, 2011 (A reporting issuer |
|
| November 7, 2014 |
Exhibit 99.83 November 7, 2014 Consent of Independent Auditor We hereby consent to the incorporation by reference in this registration statement on Form 40-F of Cipher Pharmaceuticals Inc. of our reports dated February 25, 2014, relating to the financial statements, which comprise the balance sheets as at December 31, 2013 and December 31, 2012, and the statements of operations and comprehensive i |
|
| November 7, 2014 |
EX-99.74 75 a14-234141ex99d74.htm EX-99.74 Exhibit 99.74 99.74 News Release Dated October 29, 2014 INVESTOR RELATIONS CONTACT: Craig Armitage (416) 815-0700 ext. 278 [email protected] Toronto Stock Exchange Symbol: DND CIPHER REPORTS FINANCIAL RESULTS FOR Q3 2014 - Company also announces application to list on NASDAQ - MISSISSAUGA, Ontario, October 29, 2014 - Cipher Pharmaceuticals Inc. (TS |
|
| November 7, 2014 |
CIPHER PHARMACEUTICALS INC. NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 2, 2014 Exhibit 99.53 99.53 Notice of 2014 Annual Meeting CIPHER PHARMACEUTICALS INC. NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 2, 2014 NOTICE IS HEREBY GIVEN that the Annual Meeting (the “Meeting”) of the common shareholders of Cipher Pharmaceuticals Inc. (“Cipher” or the “Corporation”) will be held on Friday, May 2, 2014 at the offices of Goodmans LLP, Bay Adelaide Centre, 333 Bay Stree |
|
| November 7, 2014 |
Exhibit 99.44 99.44 Material Change Report Dated March 14, 2014 MATERIAL CHANGE REPORT Item 1. Name and Address of Company Cipher Pharmaceuticals Inc. 5650 Tomken Rd., Unit 16 Mississauga, ON L4W 4P1 Item 2. Date of Material Change March 13, 2014 Item 3. News Release A news release was issued by Cipher Pharmaceuticals Inc. (the “Company”) on March 14, 2014. A copy of the news release is attached h |
|
| November 7, 2014 |
Exhibit 99.35 99.35 News Release Dated October 30, 2013 INVESTOR RELATIONS CONTACT: Craig Armitage TMX Equicom (416) 815-0700 ext. 278 [email protected] FOR IMMEDIATE RELEASE Toronto Stock Exchange Symbol: DND CIPHER REPORTS RECORD FINANCIAL RESULTS FOR Q3 2013 Revenue increases to $5.6 million and earnings per share rise to $0.14 MISSISSAUGA, Ontario, October 30, 2013 — Cipher Pharmaceutic |
|
| November 7, 2014 |
CIPHER MANAGEMENT’S DISCUSSION AND ANALYSIS June 30, 2013 Exhibit 99.25 99.25 Management’s Discussion and Analysis for the Three and Six Months Ended June 30, 2013 CIPHER MANAGEMENT’S DISCUSSION AND ANALYSIS June 30, 2013 The following is a discussion and analysis of the operating results and financial position of Cipher Pharmaceuticals Inc. (“Cipher” or “the Company”) for the three months ended June 30, 2013. This document should be read in conjunction |
|
| November 7, 2014 |
EX-99.16 17 a14-234141ex99d16.htm EX-99.16 Exhibit 99.16 99.16 News Release Dated April 29, 2013 Cipher Pharmaceuticals completes Latin American distribution and supply agreement for extended-release tramadol Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, April 29, 2013 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND; OTC: CPHMF) today announced it has entered into a definitive distribution and |
|
| November 7, 2014 |
Form 52-109F1R CERTIFICATION OF REFILED ANNUAL FILINGS Exhibit 99.07 99.07 Canadian Form 52-109F1R — Certification of Refiled Annual Filings - CEO Form 52-109F1R CERTIFICATION OF REFILED ANNUAL FILINGS This certificate is being filed on the same date that Cipher Pharmaceuticals Inc. (the “issuer”) has refilled Annual Information Form (AIF). I, Larry Andrews, President and Chief Executive Officer of Cipher Pharmaceuticals Inc., certify the following: 1 |
|
| November 7, 2014 |
CPHR / Cipher Pharmaceuticals, Inc. 40FR12B - - 40-FR12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 40-F T REGISTRATION STATEMENT PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 £ ANNUAL REPORT PURSUANT TO SECTION 13(A) OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: Commission File Number: CIPHER PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Ontario |
|
| November 7, 2014 |
CIPHER ANNOUNCES MANAGEMENT CHANGE EX-99.45 46 a14-234141ex99d45.htm EX-99.45 Exhibit 99.45 99.45 News Release Dated March 14, 2014 INVESTOR RELATIONS CONTACT: Craig Armitage TMX Equicom (416) 815-0700 ext. 278 [email protected] FOR IMMEDIATE RELEASE Toronto Stock Exchange Symbol: DND CIPHER ANNOUNCES MANAGEMENT CHANGE MISSISSAUGA, Ontario, March 14, 2014 — Cipher Pharmaceuticals Inc. (TSX: DND) (“Cipher” or “the Company”) t |
|
| November 7, 2014 |
Form 52-109F2 - Certification of Interim Filings Exhibit 99.56 99.56 Canadian Form 52-109F2 — Certification of Interim Filings - CEO Form 52-109F2 - Certification of Interim Filings I, Larry Andrews, President and Chief Executive Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Cipher Pharmaceuticals Inc. (the “issuer”) for |
|
| November 7, 2014 |
Form 52-109F2 - Certification of Interim Filings Exhibit 99.67 99.67 Canadian Form 52-109F2 — Certification of Interim Filings — CEO Form 52-109F2 - Certification of Interim Filings I, Shawn Patrick O’Brien, President and Chief Executive Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Cipher Pharmaceuticals Inc. (the “issu |
|
| November 7, 2014 |
Exhibit 99.71 99.71 MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2014 MANAGEMENT’S DISCUSSION AND ANALYSIS September 30, 2014 The following is a discussion and analysis of the operating results and financial position of Cipher Pharmaceuticals Inc. (“Cipher” or “the Company”) for the three and nine month periods ended September 30, 2014. This document shoul |
|
| November 7, 2014 |
FORM 52-109F1R CERTIFICATION OF REFILED ANNUAL FILINGS Exhibit 99.82 FORM 52-109F1R CERTIFICATION OF REFILED ANNUAL FILINGS This certificate is being filed on the same date that Cipher Pharmaceuticals Inc. (the “issuer”) has refiled the annual financial statements of the issuer for the financial year ended December 31, 2013. I, Norman Evans, Chief Financial Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the A |
|
| November 7, 2014 |
Form 52-109F1R CERTIFICATION OF REFILED ANNUAL FILINGS Exhibit 99.08 99.08 Canadian Form 52-109F1R — Certification of Refiled Annual Filings - CFO Form 52-109F1R CERTIFICATION OF REFILED ANNUAL FILINGS This certificate is being filed on the same date that Cipher Pharmaceuticals Inc. (the “issuer”) has refilled Annual Information Form (AIF). I, Norman Evans, Chief Financial Officer of Cipher Pharmaceuticals Inc., certify the following: 1. Review: I hav |
